Summary
The Trump Administration announced that nine more pharmaceutical companies have agreed to Most-Favored-Nation (MFN) deals, bringing the total to 26, aiming to lower drug prices for Medicaid programs. While the administration claims significant savings, experts suggest the primary benefit will be for government budgets rather than individual Medicaid users, and long-term savings may be illusory due to potential price increases in other countries.